{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:25:13Z","timestamp":1781663113946,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82503606"],"award-info":[{"award-number":["82503606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["YQ2023H015"],"award-info":[{"award-number":["YQ2023H015"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Fund of the Fourth Affiliated Hospital of Harbin Medical University","award":["HYDSYRCYJ02"],"award-info":[{"award-number":["HYDSYRCYJ02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BLCA) is a lethal malignancy frequently challenged by chemoresistance and limited therapeutic options. Kinetochore-associated 1 (KNTC1) has been implicated in cancer, yet its precise role, regulatory mechanism, and therapeutic potential in BLCA remain largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed KNTC1 expression and its clinical relevance using public databases (TCGA, GEO) and clinical specimens. Functional roles of KNTC1 in proliferation, invasion, metastasis, and gemcitabine resistance were assessed through in vitro and in vivo experiments (CCK-8, transwell, xenograft models). Mechanistic insights were gained via RNA-seq, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), and luciferase reporter assays. A poly (\u00df-amino ester) (PAE)-based nanoparticle was synthesized for targeted in vivo delivery of KNTC1 siRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>KNTC1 was significantly upregulated in BLCA tissues, and its high expression correlated with poor patient prognosis. Functionally, KNTC1 promoted BLCA cell proliferation, invasion, metastasis, and gemcitabine resistance. Mechanistically, KNTC1 bound to the transcription factor E2F8 and facilitated its nuclear translocation, thereby enhancing E2F8-mediated transcriptional activation of MYC. MYC, in turn, transcriptionally upregulated KNTC1, forming a positive feedback loop that drove hyperactivation of the oncogenic PI3K\/AKT\/mTOR pathway. Silencing KNTC1, especially in combination with a MYC inhibitor (10058-F4), overcame gemcitabine resistance in vitro and in vivo. Therapeutic delivery of KNTC1 siRNA via a novel PAE nanocarrier (PAE@shKNTC1) significantly suppressed lung metastasis in a preclinical model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study identifies a novel KNTC1\/E2F8\/MYC positive feedback axis that drives BLCA tumorigenesis and chemoresistance. KNTC1 serves as both a prognostic biomarker and a promising therapeutic target, with targeted inhibition offering a potential novel strategy for BLCA treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03651-4","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:44:29Z","timestamp":1770180269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["KNTC1 initiates a KNTC1\/E2F8\/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Kailai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hecheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"3651_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"3651_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"17","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;17(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"JAMA"},{"issue":"10364","key":"3651_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(22)01188-6.","journal-title":"Lancet"},{"issue":"1","key":"3651_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"11","key":"3651_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1613683.","journal-title":"N Engl J Med"},{"key":"3651_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102187","volume":"97","author":"P Grivas","year":"2021","unstructured":"Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, et al. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: applying clinical trial findings to clinical practice. Cancer Treat Rev. 2021;97:102187. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102187.","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"3651_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1442-2042.1999.00088.x","volume":"6","author":"S Naito","year":"1999","unstructured":"Naito S, Yokomizo A, Koga H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol. 1999;6(9):427\u201339. https:\/\/doi.org\/10.1046\/j.1442-2042.1999.00088.x.","journal-title":"Int J Urol"},{"issue":"9","key":"3651_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ccell.2022.08.010","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang M, Chen X, Tan P, Wang Y, Pan X, Lin T, et al. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell. 2022;12(9):1044-1059.e8. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.010.","journal-title":"Cancer Cell"},{"issue":"6","key":"3651_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40031","volume":"15","author":"TJ Okobi","year":"2023","unstructured":"Okobi TJ, Uhomoibhi TO, Akahara DE, Odoma VA, Sanusi IA, Okobi OE, et al. Immune checkpoint inhibitors as a treatment option for bladder cancer: current evidence. Cureus. 2023;15(6):e40031. https:\/\/doi.org\/10.7759\/cureus.40031.","journal-title":"Cureus"},{"key":"3651_CR10","doi-asserted-by":"publisher","unstructured":"Hushmandi K, Farahani N, Einollahi B, Salimimoghadam S, Alimohammadi M, Liang L, Liu L, Sethi G. Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics. J Adv Res. 2025 Jun 12:S2090-1232(25)00395-9. doi: https:\/\/doi.org\/10.7759\/cureus.40031. Epub ahead of print. PMID: 40516913.","DOI":"10.7759\/cureus.40031"},{"issue":"6","key":"3651_CR11","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","volume":"174","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174(6):1347\u201360. https:\/\/doi.org\/10.1016\/j.cell.2018.08.027.","journal-title":"Cell"},{"issue":"12","key":"3651_CR12","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/ng.2798","volume":"45","author":"G Guo","year":"2013","unstructured":"Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, Ye R, Zhang S, Lin Z, Qi M, Wan S, Xie L, Fan F, Nickerson ML, Zou X, Hu X, Xing L, Lv Z, Mei H, Gao S, Liang C, Gao Z, Lu J, Yu Y, Liu C, Li L, Fang X, Jiang Z, Yang J, Li C, Zhao X, Chen J, Zhang F, Lai Y, Lin Z, Zhou F, Chen H, Chan HC, Tsang S, Theodorescu D, Li Y, Zhang X, Wang J, Yang H, Gui Y, Wang J, Cai Z. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45(12):1459\u201363. https:\/\/doi.org\/10.1038\/ng.2798. Epub 2013 Oct 13. PMID: 24121792; PMCID: PMC7512009.","journal-title":"Nat Genet"},{"key":"3651_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcdb.2021.03.008","volume":"117","author":"AP Navarro","year":"2021","unstructured":"Navarro AP, Cheeseman IM. Kinetochore assembly throughout the cell cycle. Semin Cell Dev Biol. 2021;117:62\u201374. https:\/\/doi.org\/10.1016\/j.semcdb.2021.03.008.","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"3651_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrm2163","volume":"8","author":"A Musacchio","year":"2007","unstructured":"Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007;8(5):379\u201393. https:\/\/doi.org\/10.1038\/nrm2163.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"3651_CR15","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1242\/jcs.114.17.3103","volume":"114","author":"F Sca\u00ebrou","year":"2001","unstructured":"Sca\u00ebrou F, Starr DA, Piano F, Papoulas O, Karess RE, Goldberg ML. The ZW10 and rough deal checkpoint proteins function together in a large, evolutionarily conserved complex targeted to the kinetochore. J Cell Sci. 2001;114(17):3103\u201314. https:\/\/doi.org\/10.1242\/jcs.114.17.3103.","journal-title":"J Cell Sci"},{"issue":"12","key":"3651_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/35046598","volume":"2","author":"GK Chan","year":"2000","unstructured":"Chan GK, Jablonski SA, Starr DA, Goldberg ML, Yen TJ. Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores. Nat Cell Biol. 2000;2(12):944\u20137. https:\/\/doi.org\/10.1038\/35046598.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"3651_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05140-w","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Liu R, Guo Z, Ren J, Huang J, Luo Q, et al. Shrna-mediated knockdown of KNTC1 inhibits non-small-cell lung cancer through regulating PSMB8. Cell Death Dis. 2022;13(6):685. https:\/\/doi.org\/10.1038\/s41419-022-05140-w.","journal-title":"Cell Death Dis"},{"key":"3651_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110498","volume":"101","author":"H Tong","year":"2023","unstructured":"Tong H, Liu X, Peng C, Shen B, Zhu Z. Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K\/Akt pathway. Cell Signal. 2023;101:110498. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110498.","journal-title":"Cell Signal"},{"issue":"3","key":"3651_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3892\/ijo.2019.4672","volume":"54","author":"CT Liu","year":"2019","unstructured":"Liu CT, Min L, Wang YJ, Li P, Wu YD, Zhang ST. shRNA-mediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. Int J Oncol. 2019;54(3):1053\u201360. https:\/\/doi.org\/10.3892\/ijo.2019.4672.","journal-title":"Int J Oncol"},{"issue":"1","key":"3651_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevEukaryotGeneExpr.2021037301","volume":"31","author":"H Huang","year":"2021","unstructured":"Huang H, Fan X, Qiao Y, Yang M, Ji Z. Knockdown of KNTC1 inhibits the proliferation, migration and tumorigenesis of human bladder cancer cells and induces apoptosis. Crit Rev Eukaryot Gene Expr. 2021;31(1):49\u201360. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2021037301.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"3","key":"3651_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000524204","volume":"107","author":"S Chen","year":"2023","unstructured":"Chen S, Gao Y, Chen F, Wang TB. ANLN serves as an oncogene in bladder urothelial carcinoma via activating JNK signaling pathway. Urol Int. 2023;107(3):310\u201320. https:\/\/doi.org\/10.1159\/000524204.","journal-title":"Urol Int"},{"key":"3651_CR22","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12081","volume":"26","author":"XX Wang","year":"2023","unstructured":"Wang XX, Wu HY, Yang Y, Ma MM, Zhang YW, Huang HZ, et al. CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer. Exp Ther Med. 2023;26:382. https:\/\/doi.org\/10.3892\/etm.2023.12081.","journal-title":"Exp Ther Med"},{"issue":"15","key":"3651_CR23","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-13-2761","volume":"20","author":"SK Kim","year":"2014","unstructured":"Kim SK, Roh YG, Park K, Kang TH, Kim WJ, Lee JS, et al. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Clin Cancer Res. 2014;20(15):3233\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2761.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3651_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112860","volume":"408","author":"D Yang","year":"2021","unstructured":"Yang D, Ma Y, Zhao P, Ma J, He C. HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells. Exp Cell Res. 2021;408(15):112860. https:\/\/doi.org\/10.1016\/j.yexcr.2021.112860.","journal-title":"Exp Cell Res"},{"issue":"14","key":"3651_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A. Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol. 2014;4(14):64. https:\/\/doi.org\/10.3389\/fonc.2014.00064.","journal-title":"Front Oncol"},{"issue":"7","key":"3651_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0504-6","volume":"36","author":"J Sun","year":"2017","unstructured":"Sun J, Shi R, Zhao S, Li X, Lu S, Bu H, et al. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Cancer Res. 2017;36(7):40. https:\/\/doi.org\/10.1186\/s13046-017-0504-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"3651_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.biopha.2017.05.118","volume":"92","author":"J Tian","year":"2017","unstructured":"Tian J, Lin Y, Yu J. E2F8 confers cisplatin resistance to ER + breast cancer cells via transcriptionally activating MASTL. Biomed Pharmacother. 2017;92:919\u201326. https:\/\/doi.org\/10.1016\/j.biopha.2017.05.118.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3651_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7150\/ijbs.37686","volume":"16","author":"LK Kim","year":"2020","unstructured":"Kim LK, Park SA, Eoh KJ, Heo TH, Kim YT, Kim HJ. E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer. Int J Biol Sci. 2020;16(2):320\u20139. https:\/\/doi.org\/10.7150\/ijbs.37686.","journal-title":"Int J Biol Sci"},{"key":"3651_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/bcb-2024-0083","volume":"103","author":"LY Liu","year":"2025","unstructured":"Liu LY, Tian L, Gao LH, Cui HJ, Li XM, Li YH. E2F8 facilitates malignant phenotypes of muscle-invasive bladder cancer via increasing MCM7 expression. Biochem Cell Biol. 2025;103:1\u201314. https:\/\/doi.org\/10.1139\/bcb-2024-0083.","journal-title":"Biochem Cell Biol"},{"issue":"4","key":"3651_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/CU9.0000000000000053","volume":"15","author":"C Fragkoulis","year":"2021","unstructured":"Fragkoulis C, Ntoumas G, Glykas I, Papadopoulos G, Stathouros G, Kostopoulou A, et al. Expression of proto-oncogene c-Myc in patients with urinary bladder transitional cell carcinoma. Curr Urol. 2021;15(4):231\u20133. https:\/\/doi.org\/10.1097\/CU9.0000000000000053.","journal-title":"Curr Urol"},{"issue":"3","key":"3651_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/14737140.2016.1143777","volume":"16","author":"K Schlack","year":"2016","unstructured":"Schlack K, Boegemann M, Steinestel J, Schrader AJ, Krabbe LM. The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Rev Anticancer Ther. 2016;16(3):255\u201371. https:\/\/doi.org\/10.1586\/14737140.2016.1143777.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"3651_CR32","doi-asserted-by":"publisher","first-page":"CD009294","DOI":"10.1002\/14651858.CD009294.pub3","volume":"6","author":"MA Han","year":"2021","unstructured":"Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021;6(6):CD009294. https:\/\/doi.org\/10.1002\/14651858.CD009294.pub3. PMID: 34125951; PMCID: PMC8202966.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"3651_CR33","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s41388-020-01634-z","volume":"40","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Ju L, Yuan L, Chen L, Wang G, Xu H, et al. KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer. Oncogene. 2021;40(9):1595\u2013608. https:\/\/doi.org\/10.1038\/s41388-020-01634-z.","journal-title":"Oncogene"},{"issue":"2","key":"3651_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/nu14020369","volume":"14","author":"J Rutz","year":"2022","unstructured":"Rutz J, Maxeiner S, Juengel E, Chun FK, Tsaur I, Blaheta RA. Olive mill wastewater inhibits growth and proliferation of cisplatin- and gemcitabine-resistant bladder cancer cells in vitro by down-regulating the Akt\/mTOR-signaling pathway. Nutrients. 2022;14(2):369. https:\/\/doi.org\/10.3390\/nu14020369.","journal-title":"Nutrients"},{"issue":"3","key":"3651_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.bjc.6603242","volume":"95","author":"V Mey","year":"2006","unstructured":"Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer. 2006;95(3):289\u201397. https:\/\/doi.org\/10.1038\/sj.bjc.6603242. (Epub 2006 Jul 25. PMID: 16868547; PMCID: PMC2360654).","journal-title":"Br J Cancer"},{"issue":"1","key":"3651_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/BLC-150038","volume":"2","author":"W Abida","year":"2016","unstructured":"Abida W, Milowsky MI, Ostrovnaya I, Gerst SR, Rosenberg JE, Voss MH, et al. Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma. Bladder Cancer. 2016;2(1):111\u20137 (PMID: 27376132; PMCID: PMC4927849).","journal-title":"Bladder Cancer"},{"issue":"30","key":"3651_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.18632\/oncotarget.1545","volume":"5","author":"HK Seo","year":"2014","unstructured":"Seo HK, Ahn KO, Jung NR, Shin JS, Park WS, Lee KH, et al. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. Oncotarget. 2014;5(30):326\u201337. https:\/\/doi.org\/10.18632\/oncotarget.1545.","journal-title":"Oncotarget"},{"issue":"20","key":"3651_CR38","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.7150\/thno.102730","volume":"15","author":"Z Deng","year":"2025","unstructured":"Deng Z, Zhou F, Li M, Jin W, Yu J, Wang G, et al. DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization. Theranostics. 2025;15(20):2375\u201392. https:\/\/doi.org\/10.7150\/thno.102730.","journal-title":"Theranostics"},{"issue":"2","key":"3651_CR39","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CAD.0b013e3280109424","volume":"18","author":"CP Lin","year":"2007","unstructured":"Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs. 2007;18(2):161\u201370. https:\/\/doi.org\/10.1097\/CAD.0b013e3280109424.","journal-title":"Anticancer Drugs"},{"key":"3651_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.biopha.2015.05.019","volume":"73","author":"M Zhang","year":"2015","unstructured":"Zhang M, Fan HY, Li SC. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed Pharmacother. 2015;73:123\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2015.05.019.","journal-title":"Biomed Pharmacother"},{"issue":"16","key":"3651_CR41","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.biomaterials.2008.02.018","volume":"29","author":"D Jere","year":"2008","unstructured":"Jere D, Xu CX, Arote R, Yun CH, Cho MH, Cho CS. Poly(beta-amino ester) as a carrier for si\/shRNA delivery in lung cancer cells. Biomaterials. 2008;29(16):2535\u201347. https:\/\/doi.org\/10.1016\/j.biomaterials.2008.02.018.","journal-title":"Biomaterials"},{"issue":"12","key":"3651_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307809121","volume":"121","author":"N Nabar","year":"2024","unstructured":"Nabar N, Dacoba TG, Covarrubias G, Romero-Cruz D, Hammond PT. Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies. Proc Natl Acad Sci U S A. 2024;121(12):e2307809121. https:\/\/doi.org\/10.1073\/pnas.2307809121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3651_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.biomaterials.2016.10.035","volume":"113","author":"L Giraud","year":"2017","unstructured":"Giraud L, Viricel W, Leblond J, Giasson S. Single stranded siRNA complexation through non-electrostatic interactions. Biomaterials. 2017;113:230\u201342. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.10.035.","journal-title":"Biomaterials"},{"issue":"6","key":"3651_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01575-z","volume":"21","author":"A Du","year":"2022","unstructured":"Du A, Li S, Zhou Y, Disoma C, Liao Y, Zhang Y, et al. M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. Mol Cancer. 2022;21(6):109. https:\/\/doi.org\/10.1186\/s12943-022-01575-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"3651_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11190-0","volume":"10","author":"S Liu","year":"2019","unstructured":"Liu S, Gao Y, Zhou D, Zeng M, Alshehri F, Newland B, et al. Highly branched poly(\u00df-amino ester) delivery of minicircle DNA for transfection of neurodegenerative disease related cells. Nat Commun. 2019;10(1):3307. https:\/\/doi.org\/10.1038\/s41467-019-11190-0.","journal-title":"Nat Commun"},{"key":"3651_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125882","volume":"248","author":"M Borhaninia","year":"2023","unstructured":"Borhaninia M, Zahiri M, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. Self-targeted hyaluronic acid-b-poly (\u00df-amino ester) pH-switchable polymersome for guided doxorubicin delivery to metastatic breast cancer. Int J Biol Macromol. 2023;248:125882. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125882.","journal-title":"Int J Biol Macromol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03651-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:50Z","timestamp":1781651030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03651-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03651-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures involving human subjects received ethical approval from the Ethics Committee of the Fourth Affiliated Hospital of Harbin Medical University, under the approval number 2021-WZYSLLSC-31. This research undertaking complied fully with the Declaration of Helsinki, and participant consent was obtained in writing prior to the study. Similarly, work with animals was carried out according to established guidelines (NIH Publication No. 85\u201323, revised 1985) and was reviewed and sanctioned by the Institutional Animal Care and Use Committee at Harbin Medical University (Approval No. 2022-SCILLSC-30).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved submission to this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}